Aethlon Medical Inc EV/EBIT
Was ist das EV/EBIT von Aethlon Medical Inc?
EV/EBIT von Aethlon Medical Inc ist N/A
Was ist die Definition von EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT von Unternehmen in Industrials Sektor auf NASDAQ im Vergleich zu Aethlon Medical Inc
Was macht Aethlon Medical Inc?
the aethlon medical (nasdaq:aemd) mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. our aethlon adapt™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. the aethlon adapt™ product pipeline includes the hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as hiv and hepatitis c.
Unternehmen mit ev/ebit ähnlich Aethlon Medical Inc
- Central African Gold hat EV/EBIT von N/A
- AmWolf Capital hat EV/EBIT von N/A
- Societa Editoriale Il Fatto S.p.A hat EV/EBIT von N/A
- Aspira Women's Health hat EV/EBIT von N/A
- Eurolife Brands hat EV/EBIT von N/A
- The Alkaline Water hat EV/EBIT von N/A
- Aethlon Medical Inc hat EV/EBIT von N/A
- Polo Resources hat EV/EBIT von N/A
- Taysha Gene Therapies hat EV/EBIT von N/A
- Universal Ibogaine hat EV/EBIT von N/A
- Powerlong Coml Mgmt Hldg Ltd hat EV/EBIT von N/A
- Purple Innovation Inc hat EV/EBIT von N/A
- Oncopeptides AB (publ) hat EV/EBIT von N/A